Loracarbef (Italian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Loracarbef" in Italian language version.

refsWebsite

Global rank Italian rank

18nih.gov

4^th place

9^th place

nih.gov

ncbi.nlm.nih.gov

Nelson JD, Shelton S, Kusmiesz H, Pharmacokinetics of LY163892 in infants and children, in Antimicrobial Agents and Chemotherapy, vol. 32, n. 11, novembre 1988, pp. 1738–9, PMC 175962, PMID 3252754.
Roller S, Lode H, Stelzer I, Deppermann KM, Boeckh M, Koeppe P, Pharmacokinetics of loracarbef and interaction with acetylcysteine, in Eur. J. Clin. Microbiol. Infect. Dis., vol. 11, n. 9, settembre 1992, pp. 851–5, PMID 1468429.
DeSante KA, Zeckel ML, Pharmacokinetic profile of loracarbef, in Am. J. Med., vol. 92, 6A, giugno 1992, pp. 16S–19S, PMID 1621740.
Dere WH, Farlow D, Therasse DG, Jacobson KD, Guerra FJ, Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute purulent bacterial bronchitis, in Clin Ther, vol. 14, n. 2, 1992, pp. 166–77, PMID 1611641.
Zeckel ML, Jacobson KD, Guerra FJ, Therasse DG, Farlow D, Loracarbef (LY163892) versus amoxicillin/clavulanate in the treatment of acute bacterial exacerbations of chronic bronchitis, in Clin Ther, vol. 14, n. 2, 1992, pp. 214–29, PMID 1611645.
Zeckel ML, Loracarbef (LY163892) in the treatment of acute exacerbations of chronic bronchitis: results of U.S. and European comparative clinical trials, in Am. J. Med., vol. 92, 6A, giugno 1992, pp. 58S–64S, PMID 1621746.
Hyslop DL, Jacobson K, Guerra FJ, Loracarbef (LY163892) versus amoxicillin/clavulanate in bronchopneumonia and lobar pneumonia, in Clin Ther, vol. 14, n. 2, 1992, pp. 254–67, PMID 1611648.
Hyslop DL, Efficacy and safety of loracarbef in the treatment of pneumonia, in Am. J. Med., vol. 92, 6A, giugno 1992, pp. 65S–69S, PMID 1621747.
Moellering RC, Jacobs NF, Advances in outpatient antimicrobial therapy: loracarbef, in Am. J. Med., vol. 92, 6A, giugno 1992, pp. 1S, PMID 1352425.
Doern GV, Vautour R, Parker D, Tubert T, Torres B, In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis, in Antimicrobial Agents and Chemotherapy, vol. 35, n. 7, luglio 1991, pp. 1504–7, PMC 245202, PMID 1929318.
Kusmiesz H, Shelton S, Brown O, Manning S, Nelson JD, Loracarbef concentrations in middle ear fluid, in Antimicrobial Agents and Chemotherapy, vol. 34, n. 10, ottobre 1990, pp. 2030–1, PMC 171986, PMID 2291672.
Gan VN, Kusmiesz H, Shelton S, Nelson JD, Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media, in Antimicrobial Agents and Chemotherapy, vol. 35, n. 5, maggio 1991, pp. 967–71, PMC 245137, PMID 1854178.
Arguedas AG, Arrieta AC, Stutman HR, Akaniro JC, Marks MI, In-vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid, in J. Antimicrob. Chemother., vol. 27, n. 3, marzo 1991, pp. 311–8, PMID 1903788.
Foshee WS, Qvarnberg Y, Comparative United States and European trials of loracarbef in the treatment of acute otitis media, in Pediatr. Infect. Dis. J., vol. 11, 8 Suppl, agosto 1992, pp. S12–9, PMID 1513607.
Hyslop DL, Bischoff W, Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis, in Am. J. Med., vol. 92, 6A, giugno 1992, pp. 86S–94S, PMID 1621752.
Iravani A, Loracarbef versus cefaclor in the treatment of urinary tract infections in women, in Antimicrobial Agents and Chemotherapy, vol. 35, n. 4, aprile 1991, pp. 750–2, PMC 245091, PMID 2069382.
Iravani A, Loracarbef versus cefaclor in the treatment of cystitis and asymptomatic bacteriuria, in Clin Ther, vol. 14, n. 1, 1992, pp. 54–63, PMID 1576626.
Therasse DG, Farlow DS, Davidson RL, et al., Effects of renal dysfunction on the pharmacokinetics of loracarbef, in Clin. Pharmacol. Ther., vol. 54, n. 3, settembre 1993, pp. 311–6, PMID 8375126.